Unknown

Dataset Information

0

Targeted Next-Generation Sequencing Analysis Predicts the Recurrence in Resected Lung Adenocarcinoma Harboring EGFR Mutations.


ABSTRACT: Targeted NGS, widely applied to identify driver oncogenes in advanced lung adenocarcinoma, may also be applied to resected early stage cancers. We investigated resected EGFR-mutated lung adenocarcinoma mutation profiles to evaluate prognostic impacts. Tissues from 131 patients who had complete resection of stage I-IIIA EGFR-mutated lung adenocarcinoma were analyzed by targeted NGS for 207 cancer-related genes. Recurrence free survival (RFS) was estimated according to genetic alterations using the Kaplan-Meier method and Cox proportional regression analysis. The relapse rate was 25.2% (33/131). Five-year RFS of stages IA, IB, II, and IIIA were 82%, 75%, 35%, and 0%, respectively (p < 0.001). RFS decreased with the number of co-mutations (p = 0.025). Among co-mutations, the CTNNB1 mutation was associated with short RFS in a multivariate analysis (hazard ratio: 5.4, 95% confidence interval: 2.1-14.4; p = 0.001). TP53 mutations were associated with short RFS in stage IB-IIIA (p = 0.01). RFS was shorter with EGFR exon 19 deletion (19-del) than with mutation 21-L858R in stage IB-IIIA tumors (p = 0.008). Among 19-del subtypes, pL747_P753delinS (6/56, 8.9%) had shorter RFS than pE746_A750del (39/56, 69.6%), the most frequent subtype (p = 0.004).

SUBMITTER: Kim IA 

PROVIDER: S-EPMC8306820 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC6795151 | biostudies-literature
| S-EPMC8184531 | biostudies-literature
| S-EPMC6275825 | biostudies-literature
| S-EPMC9510045 | biostudies-literature
| S-EPMC4332630 | biostudies-literature
| S-EPMC5123695 | biostudies-literature
| S-EPMC5797192 | biostudies-literature
| S-EPMC5522272 | biostudies-other
| S-EPMC5021053 | biostudies-literature
| S-EPMC9177106 | biostudies-literature